TG Therapeutics (TGTX) Misses Q4 EPS by 12c

TG Therapeutics (NASDAQ: TGTX) reported Q4 EPS of ($0.39), $0.12 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $80 thousand versus the consensus estimate of $1.83 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)